- Home
- CSTL vs AIP Comparison
CSTL vs AIP Comparison
Compare CSTL & AIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- AIP
- Stock Information
- Founded
- CSTL 2007
- AIP 2003
- Country
- CSTL United States
- AIP United States
- Employees
- CSTL N/A
- AIP N/A
- Industry
- CSTL Medical Specialities
- AIP Semiconductors
- Sector
- CSTL Health Care
- AIP Technology
- Exchange
- CSTL Nasdaq
- AIP Nasdaq
- Market Cap
- CSTL 661.7M
- AIP 569.4M
- IPO Year
- CSTL 2019
- AIP 2021
- Fundamental
- Price
- CSTL $22.14
- AIP $12.94
- Analyst Decision
- CSTL Strong Buy
- AIP Strong Buy
- Analyst Count
- CSTL 6
- AIP 3
- Target Price
- CSTL $37.67
- AIP $15.00
- AVG Volume (30 Days)
- CSTL 296.4K
- AIP 834.7K
- Earning Date
- CSTL 11-03-2025
- AIP 11-04-2025
- Dividend Yield
- CSTL N/A
- AIP N/A
- EPS Growth
- CSTL N/A
- AIP N/A
- EPS
- CSTL N/A
- AIP N/A
- Revenue
- CSTL $346,269,000.00
- AIP $63,236,000.00
- Revenue This Year
- CSTL N/A
- AIP $19.05
- Revenue Next Year
- CSTL N/A
- AIP $17.96
- P/E Ratio
- CSTL N/A
- AIP N/A
- Revenue Growth
- CSTL 20.40
- AIP 18.64
- 52 Week Low
- CSTL $14.59
- AIP $5.46
- 52 Week High
- CSTL $35.84
- AIP $14.88
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- AIP 59.04
- Support Level
- CSTL $22.16
- AIP $12.35
- Resistance Level
- CSTL $23.19
- AIP $14.88
- Average True Range (ATR)
- CSTL 0.89
- AIP 1.00
- MACD
- CSTL -0.16
- AIP 0.14
- Stochastic Oscillator
- CSTL 10.05
- AIP 64.34
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.